arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

download Export Data

Vir Biotechnology, Inc.

VIR

$8.82 ▲ +0.05 (+0.63%) at close

10 Visible periods

27 Metrics

Absolute Benchmarks

Price Chart

Health

Weak

Bearish Absolute basis

auto_awesome

Analytical Summary

On an absolute basis, Vir Biotechnology, Inc. shows weak fundamentals, weighed down by FCF / Net Income. These readings use fixed quality thresholds rather than peer benchmarks, because too few comparable companies are available to rank against.

Market Cap $1.2B

Dividend Yield —

Revenue Growth -7.6% ↗

Op. Margin None

ROIC None

FCF / Share $-2.86 ↗

Trailing P/E —

Price / Book —

FCF Yield —

Debt / Equity —

info Valuation on last close. End-of-day price, Aug 7, 2026.

10-Year Financial Trajectory

Annual

Metric Value Trend Year over Year Percentile

Revenue Total top-line sales

$68.56M

↓ -7.6% —

Net Income Profit after all expenses

$-437.99M

↑ +16.1% —

Operating Margin Operating profit as % of sales

51.6%

↑ +34.2% —

FCF / Share Free cash flow per share

$-2.86

↑ +14.0% —

info Signals below are graded against fixed quality thresholds, not peers — peer ranking needs more comparable companies.

trending_up

Bullish Indicators

No bullish signals detected.

warning

Bearish Risks

FCF / Net IncomeFCF / Net Income of 0.91x is caution on an absolute basis (target > 1x)

Health Breakdown

Cash Quality

Financial view

Statement lens

Choose the reporting cadence, isolate a period range, or search directly for a metric.

Cadence

Annual Quarterly

Range

→

📈 Is growth accelerating? 6 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗	FY 2016 Dec 31, 2016 10-K ↗
Revenue Growth YoY (%)	-7.6% Weak ↑ Weak Improving Year-over-year change in total revenue Optimal: > 10% vs Sector: Below avg (-195%)	-13.9% Weak ↓ Weak Declining Year-over-year change in total revenue Optimal: > 10% vs Sector: Below avg (-274%)	-94.7% Weak ↓ Weak Declining Year-over-year change in total revenue Optimal: > 10% vs Sector: Below avg (-1283%)	47.5% Excellent ↓ Excellent Declining Year-over-year change in total revenue Optimal: > 10% vs Sector: Above avg (+494%)	1334.4% Excellent ↑ Excellent Improving Year-over-year change in total revenue Optimal: > 10% vs Sector: Above avg (+16580%)	843.9% Excellent ↑ Excellent Improving Year-over-year change in total revenue Optimal: > 10% vs Sector: Above avg (+10448%)	-24.2% Weak Weak Year-over-year change in total revenue Optimal: > 10% vs Sector: Below avg (-402%)	293.9% Excellent Excellent Year-over-year change in total revenue Optimal: > 10% vs Sector: Above avg (+3574%)	—	—
EPS Growth YoY (%)	17.5% Good ↑ Good Improving Year-over-year change in earnings per share Optimal: > 10%	16.6% Good Good Year-over-year change in earnings per share Optimal: > 10%	N/M	-4.4% Weak Weak Year-over-year change in earnings per share Optimal: > 10%	N/M	—	—	—	—	—
Net Income Growth YoY (%)	16.1% Good ↑ Good Improving Year-over-year change in net income	15.1% Good Good Year-over-year change in net income	N/M	-2.4% Weak ↑ Weak Improving Year-over-year change in net income	N/M	-71.0% Weak ↓ Weak Declining Year-over-year change in net income	-50.7% Weak Weak Year-over-year change in net income	-65.9% Weak Weak Year-over-year change in net income	—	—
FCF Growth YoY (%)	14.0% Fair Fair Year-over-year change in free cash flow	44.2% Excellent Excellent Year-over-year change in free cash flow	N/M	N/M	67.8% Excellent Excellent Year-over-year change in free cash flow	—	—	—	—	—
Revenue CAGR 3Y (%)	-65.1% Weak ↓ Weak Declining Compound annual revenue growth over 3 years	-59.2% Weak ↓ Weak Declining Compound annual revenue growth over 3 years	4.1% Caution ↓ Caution Declining Compound annual revenue growth over 3 years	484.5% Excellent ↑ Excellent Improving Compound annual revenue growth over 3 years	368.3% Excellent Excellent Compound annual revenue growth over 3 years	204.4% Excellent Excellent Compound annual revenue growth over 3 years	—	—	—	—
Revenue CAGR 5Y (%)	-2.1% Weak ↓ Weak Declining Compound annual revenue growth over 5 years	55.8% Excellent ↓ Excellent Declining Compound annual revenue growth over 5 years	51.9% Excellent Excellent Compound annual revenue growth over 5 years	259.0% Excellent Excellent Compound annual revenue growth over 5 years	—	—	—	—	—	—

💰 Are margins durable? 5 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗	FY 2016 Dec 31, 2016 10-K ↗
Operating Margin (%) (%)	—	—	—	51.6% Excellent ↑ Excellent Improving Operating income as a percentage of revenue Optimal: > 15% vs Sector: Above avg (+244%)	38.4% Excellent Excellent Operating income as a percentage of revenue Optimal: > 15% vs Sector: Above avg (+156%)	-388.9% Weak Weak Operating income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-2693%)	—	—	—	—
Effective Tax Rate (%) (%)	-0.0% Excellent ↓ Excellent Declining Actual taxes paid relative to pre-tax income Optimal: 15-25%	0.2% Excellent ↓ Excellent Declining Actual taxes paid relative to pre-tax income Optimal: 15-25%	2.1% Excellent ↓ Excellent Declining Actual taxes paid relative to pre-tax income Optimal: 15-25%	31.6% Weak ↑ Weak Improving Actual taxes paid relative to pre-tax income Optimal: 15-25%	3.9% Excellent ↑ Excellent Improving Actual taxes paid relative to pre-tax income Optimal: 15-25%	-0.0% Excellent ↓ Excellent Declining Actual taxes paid relative to pre-tax income Optimal: 15-25%	-0.1% Excellent ↓ Excellent Declining Actual taxes paid relative to pre-tax income Optimal: 15-25%	0.4% Excellent Excellent Actual taxes paid relative to pre-tax income Optimal: 15-25%	13.5% Excellent Excellent Actual taxes paid relative to pre-tax income Optimal: 15-25%	—
Profit Margin (%) (%)	—	—	—	31.9% Excellent ↑ Excellent Improving Net income as a percentage of revenue Optimal: > 15% vs Sector: Above avg (+166%)	48.3% Excellent Excellent Net income as a percentage of revenue Optimal: > 15% vs Sector: Above avg (+302%)	-391.1% Weak Weak Net income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-3359%)	—	—	—	—
FCF Margin (%) (%)	—	—	—	98.7% Excellent ↑ Excellent Improving Free cash flow as a percentage of revenue Optimal: > 10%	-6.3% Weak Weak Free cash flow as a percentage of revenue Optimal: > 10%	-258.6% Weak Weak Free cash flow as a percentage of revenue Optimal: > 10%	—	—	—	—
FCF / Net Income (x)	0.91x Caution ↓ Caution Declining Free cash flow relative to reported net income Optimal: > 1x	0.87x Caution ↓ Caution Declining Free cash flow relative to reported net income Optimal: > 1x	1.30x Good ↑ Good Improving Free cash flow relative to reported net income Optimal: > 1x	3.09x Excellent ↑ Excellent Improving Free cash flow relative to reported net income Optimal: > 1x	-0.13x Weak ↓ Weak Declining Free cash flow relative to reported net income Optimal: > 1x	0.66x Weak ↓ Weak Declining Free cash flow relative to reported net income Optimal: > 1x	0.79x Caution ↓ Caution Declining Free cash flow relative to reported net income Optimal: > 1x	0.88x Caution Caution Free cash flow relative to reported net income Optimal: > 1x	0.99x Caution Caution Free cash flow relative to reported net income Optimal: > 1x	—

🎯 Is capital allocation efficient? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗	FY 2016 Dec 31, 2016 10-K ↗
Return on Invested Capital (%)	—	—	—	—	28.3% Excellent ↑ Excellent Improving Return earned on debt + equity capital invested Optimal: > 10%	-41.4% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-42.0% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	66.0% Excellent Excellent Return earned on debt + equity capital invested Optimal: > 10%	102.3% Excellent Excellent Return earned on debt + equity capital invested Optimal: > 10%	—
Return on Capital (%) (%)	-47.8% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-42.0% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-35.7% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	29.7% Excellent ↑ Excellent Improving Operating profit relative to total assets Optimal: > 10%	21.5% Excellent ↑ Excellent Improving Operating profit relative to total assets Optimal: > 10%	-32.3% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-34.8% Weak Weak Operating profit relative to total assets Optimal: > 10%	-61.9% Weak Weak Operating profit relative to total assets Optimal: > 10%	—	—
Return on Common Equity (%) (%)	—	—	—	—	36.9% Excellent ↑ Excellent Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+146%)	-41.7% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-378%)	-41.2% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-375%)	64.7% Excellent Excellent Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+331%)	101.4% Excellent Excellent Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+576%)	—

⚖️ Is the balance sheet risky? 1 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗	FY 2016 Dec 31, 2016 10-K ↗
Net Debt (USD)	$-232.19M	$-222.95M	$-241.58M	$-848.63M	$-347.81M	$-436.57M	$-109.33M	$-47.60M	$-187.92M	—

📊 What does each share earn? 6 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗	FY 2016 Dec 31, 2016 10-K ↗
Revenue per Share (USD)	$0.49	$0.54	$0.64	$12.18	$8.43	$0.64	—	—	—	—
Basic EPS, GAAP (USD)	$-3.16	$-3.83	$-4.59	$3.89	$4.07	$-2.51	—	—	—	—
Free Cash Flow per Share (USD)	$-2.86	$-3.33	$-5.97	$12.03	$-0.53	$-1.66	—	—	—	—
Book Value per Share (USD)	—	—	—	—	$10.92	$5.63	$3.94	$-20.23	—	—
Tangible Book Value per Share (USD)	—	—	—	—	$10.53	$5.23	$3.45	$-26.31	—	—
Basic Weighted Avg Shares (shares)	138.52M	136.25M	134.13M	132.61M	129.88M	119.16M	—	—	—	—

🏦 How resilient is the balance sheet? 2 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗	FY 2016 Dec 31, 2016 10-K ↗
Working Capital (USD)	$421.26M	$922.80M	$1.41B	$2.01B	$1.22B	$673.30M	$343.79M	$77.88M	—	—
Total Equity (USD)	—	—	—	—	$1.43B	$716.85M	$423.94M	$-179.18M	$-68.92M	$-7.97M

📋 What is driving earnings? 4 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗	FY 2017 Dec 31, 2017 10-K ↗	FY 2016 Dec 31, 2016 10-K ↗
Sales/Revenue/Turnover (USD)	$68.56M	$74.20M	$86.18M	$1.62B	$1.10B	$76.37M	$8.09M	$10.67M	$2.71M	—
Depreciation Expense (USD)	$11.68M	$14.56M	$19.45M	$6.25M	$5.28M	$4.40M	$3.29M	$1.62M	$255.00K	—
Net Income, GAAP (USD)	$-437.99M	$-521.96M	$-615.06M	$515.84M	$528.58M	$-298.67M	$-174.68M	$-115.88M	$-69.85M	—
Operating Cash Flow (USD)	$-391.78M	$-446.35M	$-778.78M	$1.66B	$-47.59M	$-190.94M	$-129.63M	$-94.10M	$-66.38M	—

⌨️ Keyboard Shortcuts

/ Search

Esc Clear

A Annual

Q Quarterly

1-7 Jump to category

R Reset

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 10 years · 35 quarters

Vir Biotechnology, Inc.

Analytical Summary

10-Year Financial Trajectory

Bullish Indicators

Bearish Risks

Health Breakdown

Statement lens

Benchmark Lens

Benchmarks unavailable

Compare VIR with peers